Option chain shows key data for Lanxess's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lanxess.

Lanxess (OTC:LNXSF) Stock, Option Chain

Lanxess AG is a German chemical company that was originally spun out of Bayer. Lanxess has visibly decommoditised its portfolio in recent years by divesting its synthetic rubber business and is moving toward becoming a specialty chemicals company in the fields of consumer protection chemicals, specialty additives, intermediates, and engineering plastics.

News

Tech

AMZN

LNXSF

PLTR

Palantir Technologies Inc (NASDAQ: PLTR) announced Friday its new Enterprise Resource Planning (ERP) system with Amazon.com, Inc. (NASDAQ: 

Palantir And AWS Team Up For ERP Suite

Intraday Update

Markets

Movers

ACTA

ALDX

ARRY

CHMT

CPPL

EXEL

GWPH

LPCN

RGSE

SMMT

ZYNE

12 Biggest Mid-Day Gainers For Monday

Benzinga&#39;s Volume Movers

Lanxess AG

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>For Alcoa Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>), Argus Research upgraded the previous rating of Hold to Buy. Alcoa earned $1.49 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $51.17 and a 52-week-low of $10.98. At the end of the last trading period, Alcoa closed at $48.00.</li>
<li>According to Cowen &amp; Co., the prior rating for Knight-Swift Transportation Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) was changed from Market Perform to Outperform. For the second quarter, Knight-Swift had an EPS of $0.98, compared to year-ago quarter EPS of $0.57. The current stock performance of Knight-Swift shows a 52-week-high of $54.00 and a 52-week-low of $37.07. Moreover, at the end of the last trading period, the closing price was at $51.72.</li>
<li>JP Morgan upgraded the previous rating for SM Energy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) from Neutral to Overweight. In the second quarter, SM Energy showed an EPS of $0.01, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $26.86 and a 52-week-low of $1.34. At the end of the last trading period, SM Energy closed at $20.26.</li>
<li>JP Morgan upgraded the previous rating for Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Underweight to Neutral. For the second quarter, Range Resources had an EPS of $0.24, compared to year-ago quarter EPS of $0.10. The stock has a 52-week-high of $18.82 and a 52-week-low of $5.93. At the end of the last trading period, Range Resources closed at $18.39.</li>
<li>According to Guggenheim, the prior rating for Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) was changed from Neutral to Buy. For the second quarter, Sarepta Therapeutics had an EPS of $1.52, compared to year-ago quarter EPS of $1.51. The current stock performance of Sarepta Therapeutics shows a 52-week-high of $181.83 and a 52-week-low of $65.30. Moreover, at the end of the last trading period, the closing price was at $80.28.</li>
<li>For Schneider National Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>), Cowen &amp; Co. upgraded the previous rating of Market Perform to Outperform. In the second quarter, Schneider National showed an EPS of $0.60, compared to $0.26 from the year-ago quarter. The current stock performance of Schneider National shows a 52-week-high of $27.15 and a 52-week-low of $20.20. Moreover, at the end of the last trading period, the closing price was at $21.98.</li>
<li>According to Cowen &amp; Co., the prior rating for Werner Enterprises Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) was changed from Market Perform to Outperform. Werner Enterprises earned $0.86 in the second quarter, compared to $0.62 in the year-ago quarter. At the moment, the stock has a 52-week-high of $49.76 and a 52-week-low of $35.15. Werner Enterprises closed at $45.96 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>For Southwestern Energy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWN#NYSE">SWN</a>), JP Morgan downgraded the previous rating of Neutral to Underweight. Southwestern Energy earned $0.19 in the second quarter, compared to $0.00 in the year-ago quarter. The current stock performance of Southwestern Energy shows a 52-week-high of $5.85 and a 52-week-low of $2.18. Moreover, at the end of the last trading period, the closing price was at $5.16.</li>
<li>According to JP Morgan, the prior rating for Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) was changed from Overweight to Neutral. For the second quarter, Chevron had an EPS of $1.71, compared to year-ago quarter EPS of $1.59. At the moment, the stock has a 52-week-high of $113.11 and a 52-week-low of $65.16. Chevron closed at $96.20 at the end of the last trading period.</li>
<li>Ladenburg Thalmann downgraded the previous rating for Itamar Medical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITMR#NASDAQ">ITMR</a>) from Buy to Neutral. For the second quarter, Itamar Medical had an EPS of $0.20, compared to year-ago quarter EPS of $0.17. The current stock performance of Itamar Medical shows a 52-week-high of $30.40 and a 52-week-low of $16.36. Moreover, at the end of the last trading period, the closing price was at $30.40.</li>
<li>According to BTIG, the prior rating for Integra Lifesciences Holdings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) was changed from Buy to Neutral. In the second quarter, Integra Lifesciences showed an EPS of $0.79, compared to $0.33 from the year-ago quarter. At the moment, the stock has a 52-week-high of $77.40 and a 52-week-low of $42.12. Integra Lifesciences closed at $69.95 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>With an Outperform rating, Northland Capital Markets initiated coverage on Motion Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTN#NASDAQ">MOTN</a>). The price target seems to have been set at $16.00 for Motion Acquisition. At the moment, the stock has a 52-week-high of $11.75 and a 52-week-low of $9.77. Motion Acquisition closed at $9.95 at the end of the last trading period.</li>
<li>With a Buy rating, Maxim Group initiated coverage on Unisys Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>). The price target seems to have been set at $35.00 for Unisys. Unisys earned $0.68 in the second quarter, compared to $0.15 in the year-ago quarter. At the moment, the stock has a 52-week-high of $28.60 and a 52-week-low of $10.12. Unisys closed at $23.30 at the end of the last trading period.</li>
<li>Maxim Group initiated coverage on 180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) with a Buy rating. The price target for 180 Life Sciences is set to $11.00. In the second quarter, 180 Life Sciences earned $0.75. The current stock performance of 180 Life Sciences shows a 52-week-high of $13.05 and a 52-week-low of $1.90. Moreover, at the end of the last trading period, the closing price was at $5.67.</li>
<li>Guggenheim initiated coverage on Surrozen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) with a Buy rating. The price target for Surrozen is set to $20.00.&nbsp;At the end of the last trading period, Surrozen closed at $10.13.</li>
<li>With a Neutral rating, Citigroup initiated coverage on EVgo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>). The price target seems to have been set at $10.00 for EVgo. In the second quarter, EVgo earned $4.49. At the moment, the stock has a 52-week-high of $16.24 and a 52-week-low of $7.90. EVgo closed at $7.99 at the end of the last trading period.</li>
<li>With a Neutral rating, Citigroup initiated coverage on CCC Intelligent Solutions Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NYSE">CCCS</a>). The price target seems to have been set at $13.00 for CCC Intelligent Solutions. At the end of the last trading period, CCC Intelligent Solutions closed at $11.29.</li>
<li>BTIG initiated coverage on Sonnet BioTherapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) with a Buy rating. The price target for Sonnet BioTherapeutics is set to $5.00. In the third quarter, Sonnet BioTherapeutics showed an EPS of $0.27, compared to $0.44 from the year-ago quarter. At the moment, the stock has a 52-week-high of $3.42 and a 52-week-low of $0.55. Sonnet BioTherapeutics closed at $0.56 at the end of the last trading period.</li>
<li>B of A Securities initiated coverage on Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) with a Buy rating. The price target for Lucid Gr is set to $30.00.&nbsp;Moreover, at the end of the last trading period, the closing price was at $18.95.</li>
<li>Cantor Fitzgerald initiated coverage on Equillium Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) with an Overweight rating. The price target for Equillium is set to $14.00. Equillium earned $0.31 in the second quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $11.33 and a 52-week-low of $3.47. At the end of the last trading period, Equillium closed at $5.40.</li>
<li>Wells Fargo initiated coverage on Wynn Resorts Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Equal-Weight rating. The price target for Wynn Resorts is set to $112.00. Wynn Resorts earned $1.12 in the second quarter, compared to $6.14 in the year-ago quarter. The stock has a 52-week-high of $143.88 and a 52-week-low of $67.70. At the end of the last trading period, Wynn Resorts closed at $92.25.</li>
<li>With a Equal-Weight rating, Wells Fargo initiated coverage on Las Vegas Sands Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>). The price target seems to have been set at $50.00 for Las Vegas Sands. In the second quarter, Las Vegas Sands showed an EPS of $0.26, compared to $1.05 from the year-ago quarter. The stock has a 52-week-high of $66.77 and a 52-week-low of $36.42. At the end of the last trading period, Las Vegas Sands closed at $38.71.</li>
<li>With an Overweight rating, Wells Fargo initiated coverage on Caesars Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>). The price target seems to have been set at $137.00 for Caesars Entertainment. In the second quarter, Caesars Entertainment showed an EPS of $0.59, compared to $1.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $113.46 and a 52-week-low of $43.07. Caesars Entertainment closed at $103.07 at the end of the last trading period.</li>
<li>Mizuho initiated coverage on SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Buy rating. The price target for SoFi Technologies is set to $28.00. For the second quarter, SoFi Technologies had an EPS of $0.48, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $24.95 and a 52-week-low of $13.56. SoFi Technologies closed at $14.50 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Analyst Ratings

ATNF

BALY

CCCS

CFLT

CHDN

DKNG

EVGO

GPOR

IART

ITMR

LCID

MOTN

PINE

RMBL

SNDR

SOFI

SONN

SRPT

SRZN

WERN

WYNN

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021

Credit Suisse upgrades Lanxess (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNXSF#OTC">LNXSF</a>) from Neutral to Outperform.

Credit Suisse Upgrades Lanxess to Outperform

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>According to DA Davidson, the prior rating for PaySign Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) was changed from Neutral to Buy. In the second quarter, PaySign showed an EPS of $0.02, compared to $0.00 from the year-ago quarter. At the moment, the stock has a 52-week-high of $7.42 and a 52-week-low of $2.38. PaySign closed at $2.47 at the end of the last trading period.</li>
<li>For Weibo Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>), Credit Suisse upgraded the previous rating of Neutral to Outperform. In the second quarter, Weibo showed an EPS of $0.79, compared to $0.50 from the year-ago quarter. The stock has a 52-week-high of $64.70 and a 52-week-low of $32.51. At the end of the last trading period, Weibo closed at $48.01.</li>
<li>For Apellis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), Wedbush upgraded the previous rating of Neutral to Outperform. For the second quarter, Apellis Pharmaceuticals had an EPS of $2.72, compared to year-ago quarter EPS of $1.57. At the moment, the stock has a 52-week-high of $73.00 and a 52-week-low of $26.38. Apellis Pharmaceuticals closed at $59.02 at the end of the last trading period.</li>
<li>According to RBC Capital, the prior rating for Oatly Group AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) was changed from Sector Perform to Outperform. In the second quarter, Oatly Group earned $0.11. The current stock performance of Oatly Group shows a 52-week-high of $29.00 and a 52-week-low of $14.87. Moreover, at the end of the last trading period, the closing price was at $15.16.</li>
<li>Nomura Instinet upgraded the previous rating for Daqo New Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) from Reduce to Neutral. Daqo New Energy earned $3.06 in the second quarter, compared to $0.47 in the year-ago quarter. At the moment, the stock has a 52-week-high of $1218.20 and a 52-week-low of $37.02. Daqo New Energy closed at $47.95 at the end of the last trading period.</li>
<li>According to Credit Suisse, the prior rating for New Fortress Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) was changed from Neutral to Outperform. For the second quarter, New Fortress Energy had an EPS of $0.03, compared to year-ago quarter EPS of $0.24. The current stock performance of New Fortress Energy shows a 52-week-high of $65.90 and a 52-week-low of $25.34. Moreover, at the end of the last trading period, the closing price was at $26.50.</li>
<li>Jefferies upgraded the previous rating for Smartsheet Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) from Hold to Buy. For the first quarter, Smartsheet had an EPS of $0.09, compared to year-ago quarter EPS of $0.11. At the moment, the stock has a 52-week-high of $85.43 and a 52-week-low of $43.64. Smartsheet closed at $68.25 at the end of the last trading period.</li>
<li>Jefferies upgraded the previous rating for Bill.com Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) from Hold to Buy. In the third quarter, Bill.com Holdings showed an EPS of $0.02, compared to $0.04 from the year-ago quarter. The stock has a 52-week-high of $211.85 and a 52-week-low of $82.19. At the end of the last trading period, Bill.com Holdings closed at $204.92.</li>
<li>According to Itau BBA, the prior rating for Ternium SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) was changed from Market Perform to Outperform. In the second quarter, Ternium showed an EPS of $5.21, compared to $0.22 from the year-ago quarter. The current stock performance of Ternium shows a 52-week-high of $56.86 and a 52-week-low of $17.02. Moreover, at the end of the last trading period, the closing price was at $54.64.</li>
<li>For SFL Corp Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFL#NYSE">SFL</a>), Jefferies upgraded the previous rating of Hold to Buy. In the second quarter, SFL Corp showed an EPS of $0.18, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $9.79 and a 52-week-low of $5.85. At the end of the last trading period, SFL Corp closed at $7.17.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>For Vipshop Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>), Credit Suisse downgraded the previous rating of Outperform to Neutral. In the second quarter, Vipshop Holdings showed an EPS of $0.32, compared to $0.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $46.00 and a 52-week-low of $13.44. Vipshop Holdings closed at $14.26 at the end of the last trading period.</li>
<li>For Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), SVB Leerink downgraded the previous rating of Outperform to Market Perform. For the second quarter, Illumina had an EPS of $1.87, compared to year-ago quarter EPS of $0.62. The current stock performance of Illumina shows a 52-week-high of $555.77 and a 52-week-low of $260.42. Moreover, at the end of the last trading period, the closing price was at $510.61.</li>
<li>According to Summit Insights Group, the prior rating for NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) was changed from Hold to Sell. NVIDIA earned $1.04 in the second quarter, compared to $2.18 in the year-ago quarter. The current stock performance of NVIDIA shows a 52-week-high of $208.75 and a 52-week-low of $115.67. Moreover, at the end of the last trading period, the closing price was at $190.40.</li>
<li>Baird downgraded the previous rating for The Toro Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) from Outperform to Neutral. For the second quarter, Toro had an EPS of $1.29, compared to year-ago quarter EPS of $0.92. The stock has a 52-week-high of $118.13 and a 52-week-low of $72.94. At the end of the last trading period, Toro closed at $111.34.</li>
<li>For Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>), Barclays downgraded the previous rating of Overweight to Equal-Weight. In the second quarter, Galapagos showed an EPS of $1.18, compared to $1.95 from the year-ago quarter. The current stock performance of Galapagos shows a 52-week-high of $190.32 and a 52-week-low of $56.79. Moreover, at the end of the last trading period, the closing price was at $59.07.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>UBS initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Sell rating. The price target for Ultragenyx Pharmaceutical is set to $73.00. In the second quarter, Ultragenyx Pharmaceutical showed an EPS of $1.81, compared to $1.12 from the year-ago quarter. The current stock performance of Ultragenyx Pharmaceutical shows a 52-week-high of $179.65 and a 52-week-low of $72.83. Moreover, at the end of the last trading period, the closing price was at $81.96.</li>
<li>With a Buy rating, Maxim Group initiated coverage on Xperi Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NASDAQ">XPER</a>). The price target seems to have been set at $31.00 for Xperi Holding. In the second quarter, Xperi Holding showed an EPS of $0.61, compared to $0.57 from the year-ago quarter. At the moment, the stock has a 52-week-high of $25.03 and a 52-week-low of $11.03. Xperi Holding closed at $20.39 at the end of the last trading period.</li>
<li>With a Buy rating, Janney Montgomery Scott initiated coverage on Beazer Homes USA Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BZH#NYSE">BZH</a>). The price target seems to have been set at $23.00 for Beazer Homes USA. In the third quarter, Beazer Homes USA showed an EPS of $1.22, compared to $0.59 from the year-ago quarter. The current stock performance of Beazer Homes USA shows a 52-week-high of $26.12 and a 52-week-low of $10.96. Moreover, at the end of the last trading period, the closing price was at $17.31.</li>
<li>SVB Leerink initiated coverage on Amryt Pharma PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMYT#NASDAQ">AMYT</a>) with an Outperform rating. The price target for Amryt Pharma is set to $22.00. Amryt Pharma earned $0.04 in the second quarter, compared to $0.12 in the year-ago quarter. The stock has a 52-week-high of $15.44 and a 52-week-low of $9.55. At the end of the last trading period, Amryt Pharma closed at $11.90.</li>
<li>Wolfe Research initiated coverage on Wheels Up Experience Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) with a Peer Perform rating. Interestingly, in the second quarter, Wheels Up Experience&#39;s EPS was $0.12. The stock has a 52-week-high of $15.00 and a 52-week-low of $7.10. At the end of the last trading period, Wheels Up Experience closed at $8.16.</li>
<li>With a Buy rating, Benchmark initiated coverage on Power Integrations Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWI#NASDAQ">POWI</a>). The price target seems to have been set at $115.00 for Power Integrations. Power Integrations earned $0.83 in the second quarter, compared to $0.66 in the year-ago quarter. The stock has a 52-week-high of $118.68 and a 52-week-low of $50.34. At the end of the last trading period, Power Integrations closed at $98.09.</li>
<li>Jefferies initiated coverage on Holley Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Buy rating. The price target for Holley is set to $18.00. Moreover, at the end of the last trading period, the closing price was at $10.82.</li>
<li>With an Outperform rating, Oppenheimer initiated coverage on Invacare Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVC#NYSE">IVC</a>). The price target seems to have been set at $11.00 for Invacare. Invacare earned $0.28 in the second quarter, compared to $0.21 in the year-ago quarter. The current stock performance of Invacare shows a 52-week-high of $10.94 and a 52-week-low of $6.39. Moreover, at the end of the last trading period, the closing price was at $7.37.</li>
<li>Citigroup initiated coverage on Talkspace Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) with a Buy rating. The price target for Talkspace is set to $7.00. For the second quarter, Talkspace had an EPS of $1.15, compared to year-ago quarter EPS of $0.05. At the moment, the stock has a 52-week-high of $9.27 and a 52-week-low of $4.60. Talkspace closed at $5.11 at the end of the last trading period.</li>
<li>With an Outperform rating, Daiwa Capital initiated coverage on Applied Materials Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>). The price target seems to have been set at $140.00 for Applied Materials. For the third quarter, &nbsp;The stock has a 52-week-high of $146.00 and a 52-week-low of $54.15. At the end of the last trading period, Applied Materials closed at $127.37.</li>
<li>Goldman Sachs initiated coverage on Finance of America Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) with a Neutral rating. The price target for Finance of America is set to $5.50. Interestingly, in the second quarter, Finance of America&#39;s EPS was $0.30. The stock has a 52-week-high of $11.65 and a 52-week-low of $4.96. At the end of the last trading period, Finance of America closed at $5.20.</li>
<li>DA Davidson initiated coverage on Motorsport Games Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) with a Buy rating. The price target for Motorsport Games is set to $15.00. Motorsport Games earned $0.50 in the second quarter. The current stock performance of Motorsport Games shows a 52-week-high of $38.00 and a 52-week-low of $8.77. Moreover, at the end of the last trading period, the closing price was at $9.11.</li>
<li>Cantor Fitzgerald initiated coverage on Portage Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) with an Overweight rating. The price target for Portage Biotech is set to $35.00. The stock has a 52-week-high of $44.98 and a 52-week-low of $13.40. At the end of the last trading period, Portage Biotech closed at $18.95.</li>
<li>With a Buy rating, HC Wainwright &amp; Co. initiated coverage on IVERIC bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISEE#NASDAQ">ISEE</a>). The price target seems to have been set at $20.00 for IVERIC bio. In the second quarter, IVERIC bio showed an EPS of $0.32, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $10.25 and a 52-week-low of $4.20. At the end of the last trading period, IVERIC bio closed at $9.07.</li>
<li>HC Wainwright &amp; Co. initiated coverage on Senseonics Holdings Inc (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) with a Buy rating. The price target for Senseonics Holdings is set to $6.00. Senseonics Holdings earned $0.42 in the second quarter, compared to $0.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.56 and a 52-week-low of $0.35. Senseonics Holdings closed at $3.12 at the end of the last trading period.</li>
<li>Jefferies initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy rating. The price target for Apellis Pharmaceuticals is set to $74.00. In the second quarter, Apellis Pharmaceuticals showed an EPS of $2.72, compared to $1.57 from the year-ago quarter. The current stock performance of Apellis Pharmaceuticals shows a 52-week-high of $73.00 and a 52-week-low of $26.38. Moreover, at the end of the last trading period, the closing price was at $59.02.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

AMAT

AMYT

APLS

BILL

DBCCF

DMZPY

GLPG

HLLY

ILMN

ISEE

MKTW

MSGM

NEXA

NVDA

OTLY

PAYS

PMVP

POWI

PRTG

RARE

SENS

SLTTF

SMAR

TALK

TLPFY

VIPS

XPER

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021

Goldman Sachs upgrades Lanxess (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LNXSF#OTC">LNXSF</a>) from Sell to Buy.

Goldman Sachs Upgrades Lanxess to Buy

Palantir Technologies Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NASDAQ">PLTR</a>) announced Friday&nbsp;<a href="https://medium.com/palantir/launching-erp-suite-to-deliver-cost-savings-for-aws-customers-ceed6e6dd927">its new </a>Enterprise Resource Planning&nbsp;(ERP) system with&nbsp;Amazon.com, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) cloud service platform Amazon Web Services (AWS) will be available to all AWS customers.
What Happened: Palantir&#39;s ERP Suite is optimized to run on&nbsp;AWS to assist customers with data integration and analysis. The suite &ldquo;has already been adopted by a number of enterprises, including BP&nbsp;and Lanxess, to enable significant cost savings within weeks,&rdquo; Palantir said in its blog.
Why It Matters: Palantir, a software company that specializes in data analytics, has created a number of platforms, including Foundry and Gotham, that are&nbsp;being used by government bodies and <a href="https://www.benzinga.com/news/21/02/19800306/n95-mask-producer-3m-expands-use-of-palantirs-foundry-platform-to-help-with-supply-chain-demand">commercial customers</a> as a business solution tool.
<a href="https://www.benzinga.com/money/how-to-buy-palantir-technologies-pltr-stock/">See also:&nbsp;How to Buy Palantir Technologies (PLTR) Stock</a>
The ERP Suite &ldquo;uses a Palantir Foundry data connector developed for ERP applications to improve data discovery, accelerate the time-to-value of ERP data, democratize workflow creation and drive faster business outcomes,&rdquo; the company stated&nbsp;in the blog.
What&rsquo;s Next: Palantir has been working with AWS over the past year on a number of different projects and believes companies that&nbsp;adopt its new ERP Suite will be quick to see results.
&ldquo;Within two weeks of installing the ERP Suite, BP&nbsp;was able to unlock approximately $50 million in working capital and has the potential to unlock further savings if applied across their worldwide supply chain,&rdquo; the company said.
The ERP suite is now available for all AWS customers and can be deployed within days.
&ldquo;We&rsquo;re excited to be working with Palantir to make this suite of tools available on AWS and to help our customers get to insights faster, unlocking the data they already have,&rdquo; said Teresa Carlson, vice president, worldwide public sector and industries at AWS.
(Photo by <a href="http://unsplash.com/@eberhardgross?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Eberhard Grossgasteiger </a>on <a href="https://unsplash.com/s/photos/clouds?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>)

&nbsp;
<ul>
<li>
		Array Biopharma Inc (NASDAQ: <a class="ticker" href="/stock/arry#NASDAQ">ARRY</a>) shares jumped 57.9 percent to $5.76 after the company disclosed that its COLUMBUS Phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma has met primary endpoint.</li>
<li>
		Lipocine Inc (NASDAQ: <a class="ticker" href="/stock/lpcn#NASDAQ">LPCN</a>) shares climbed 23.4 percent to $4.80 after the company reported positive top-line Phase 2b study results for LPCN 1111.</li>
<li>
		Chemtura Corp (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>) shares surged 15.8 percent to $32.63 as LANXESS AG NPV (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) announced Sunday, it has signed a contract to acquire the company for $33.50 per share in cash or $2.5 billion.</li>
<li>
		Actua Corp (NASDAQ: <a class="ticker" href="/stock/acta#NASDAQ">ACTA</a>) shares surged 15 percent to $ 11.81. Actua reported a deal to sell GovDelivery to an investor group led by Vista Equity Partners for $153 million in cash.</li>
<li>
		GW Pharmaceuticals PLC- ADR (NASDAQ: <a class="ticker" href="/stock/gwph#NASDAQ">GWPH</a>) climbed 14.2 percent to $122.82 as the company revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study.</li>
<li>
		Summit Therapeutics PLC (ADR) (NASDAQ: <a class="ticker" href="/stock/smmt#NASDAQ">SMMT</a>) climbed 14.1 percent to $10.03 as the company disclosed that it has received Fast Track designation from the FDA for ezutromid in the treatment of DMD.</li>
<li>
		Real Goods Solar, Inc. (NASDAQ: <a class="ticker" href="/stock/rgse#NASDAQ">RGSE</a>) shares gained 14.1 percent to $2.28. Real Goods Solar shares have tumbled 91.87 percent over the past 52 weeks, while the S&amp;P 500 index has gained 15.03 percent in the same period.</li>
<li>
		Zynerba Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="/stock/zyne#NASDAQ">ZYNE</a>) shares rose 8.2 percent to $13.69. Jefferies reiterated Buy rating and $32 price target on Zynerba Pharmaceuticals.</li>
<li>
		Aldeyra Therapeutics Inc (NASDAQ: <a class="ticker" href="/stock/aldx#NASDAQ">ALDX</a>) shares climbed 7.3 percent to $8.00. H.C. Wainwright initiated coverage on Aldeyra Therapeutics with a Buy rating.</li>
<li>
		Diebold Inc (NYSE: <a class="ticker" href="/stock/dbd#NYSE">DBD</a>) gained 6.4 percent to $26.04. JP Morgan upgraded Diebold from Neutral to Overweight.</li>
<li>
		Columbia Pipeline Partners LP (NYSE: <a class="ticker" href="/stock/cppl#NYSE">CPPL</a>) gained 6.4 percent to $16.28. TransCanada Corporation (USA) (NYSE: <a class="ticker" href="/stock/trp#NYSE">TRP</a>) offered to buy Columbia Pipeline Partners for $15.75 per share.</li>
<li>
		Exelixis, Inc. (NASDAQ: <a class="ticker" href="/stock/exel#NASDAQ">EXEL</a>) rose 2.5 percent to $15.26 as the company disclosed that it has received a $15 million milestone payment for initiation of Phase 3 study for CS-3150.</li>
</ul>

&nbsp;
<ul>
<li>
		Chemtura Corp (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>) surged 15.7 percent to $32.59. The volume of Chemtura shares traded was 4669 percent higher than normal. LANXESS AG NPV (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) announced Sunday, it has signed a contract to acquire Chemtura for $33.50 per share in cash or $2.5 billion.</li>
<li>
		GW Pharmaceuticals PLC- ADR (NASDAQ: <a class="ticker" href="/stock/gwph#NASDAQ">GWPH</a>) shares moved up 15.8 percent to $124.50. The volume of GW Pharmaceuticals traded was 922 percent higher than normal. GW Pharmaceuticals revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study.</li>
<li>
		Zynerba Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="/stock/zyne#NASDAQ">ZYNE</a>) shares gained 11.2 percent to $14.08. The volume of Zynerba Pharmaceuticals shares traded was 831 percent higher than normal. Jefferies reiterated Buy rating and $32 price target on Zynerba Pharmaceuticals..</li>
<li>
		Actua Corp (NASDAQ: <a class="ticker" href="/stock/acta#NASDAQ">ACTA</a>) shares rose 14.8 percent to $11.78. The volume of Actua shares traded was 779 percent higher than normal. Actua reported a deal to sell GovDelivery to an investor group led by Vista Equity Partners for $153 million in cash.</li>
</ul>

Benzinga's Volume Movers

<h3>
	 
	Gainers</h3>
<ul>
<li>
		Array Biopharma Inc (NASDAQ: <a class="ticker" href="/stock/arry#NASDAQ">ARRY</a>) rose 23.3 percent to $4.50 in pre-market trading after the company disclosed that its COLUMBUS Phase 3 study of encorafenib plus binimetinib for BRAF-mutant melanoma has met primary endpoint.</li>
<li>
		Chemtura Corp (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>) shares rose 17.3 percent to $33.06 in pre-market trading as LANXESS AG NPV (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) announced Sunday, it has signed a contract to acquire the company for $33.50 per share in cash or $2.5 billion.</li>
<li>
		GW Pharmaceuticals PLC- ADR (NASDAQ: <a class="ticker" href="/stock/gwph#NASDAQ">GWPH</a>) rose 12.4 percent to $120.85 in pre-market trading as the company revealed Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome. The positive results came from its randomized, double-blind and placebo-controlled final stage clinical study.</li>
<li>
		Zynerba Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="/stock/zyne#NASDAQ">ZYNE</a>) shares rose 10.6 percent to $14.00 in pre-market trading after dropping 2.54 percent on Friday.</li>
<li>
		Lam Research Corporation (NASDAQ: <a class="ticker" href="/stock/lrcx#NASDAQ">LRCX</a>) rose 5.9 percent to $97.17 in pre-market trading after declining 0.98 percent on Friday.</li>
<li>
		Vistagen Therapeutics Inc (NASDAQ: <a class="ticker" href="/stock/vtgn#NASDAQ">VTGN</a>) shares rose 4.8 percent to $4.56 in pre-market trading after gaining 3.33 percent on Friday.</li>
<li>
		Exelixis, Inc. (NASDAQ: <a class="ticker" href="/stock/exel#NASDAQ">EXEL</a>) rose 3.4 percent to $15.40 in pre-market trading as the company disclosed that it has received a $15 million milestone payment for initiation of Phase 3 study for CS-3150.</li>
</ul>

	Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.
<h3>
	Losers</h3>
<ul>
<li>
		Pain Therapeutics, Inc. (NASDAQ: <a class="ticker" href="/stock/ptie#NASDAQ">PTIE</a>) shares fell 61.5 percent to $1.05 in pre-market trading after the company reported that it has received a complete response letter from the FDA. The FDA determined that REMOXY cannot be approved.</li>
<li>
		DURECT Corporation (NASDAQ: <a class="ticker" href="/stock/drrx#NASDAQ">DRRX</a>) shares fell 40 percent to $1.02 in pre-market trading after the company reported that its licensee Pain Therapeutics has received a complete response letter from the FDA for REMOXY.</li>
<li>
		PJT Partners Inc (NYSE: <a class="ticker" href="/stock/pjt#NYSE">PJT</a>) shares fell 9.8 percent to $23.66 in pre-market trading after rising 0.81 percent on Friday.</li>
<li>
		Sorl Auto Parts, Inc. (NASDAQ: <a class="ticker" href="/stock/sorl#NASDAQ">SORL</a>) fell 9.7 percent to $3.36 in pre-market trading after declining 0.53 percent on Friday.</li>
<li>
		Cal-Maine Foods Inc (NASDAQ: <a class="ticker" href="/stock/calm#NASDAQ">CALM</a>) fell 7.5 percent to $39.00 in pre-market trading after the company reported a wider-than-expected loss for its first quarter.</li>
<li>
		Deutsche Bank AG (USA) (NYSE: <a class="ticker" href="/stock/db#NYSE">DB</a>) shares fell around 5 percent to $12.12 in pre-market trading. According to Bloomberg, Deutsche Bank could be forced to raise capital to help finance a $14 billion fee given by the U.S. Justice Department to settle a probe tied to the bank&#39;s residential mortgage-backed securities practices prior to the financial crisis. Specifically, the German bank allegedly misled investors over the quality of subprime mortgage bonds it created and sold prior to the 2008 financial crisis.</li>
<li>
		Smith &amp; Wesson Holding Corp (NASDAQ: <a class="ticker" href="/stock/swhc#NASDAQ">SWHC</a>) shares fell 4.2 percent to $26.40 in pre-market trading after slipping 0.18 percent on Friday.</li>
<li>
		Himax Technologies, Inc. (ADR) (NASDAQ: <a class="ticker" href="/stock/himx#NASDAQ">HIMX</a>) shares fell 4 percent to $10.30 in pre-market trading.</li>
</ul>

Movers & Shakers

Pre-Market Outlook

CALM

DRRX

HIMX

LRCX

PTIE

SORL

SWHC

VTGN

15 Stocks Moving In Monday's Pre-Market Session

Some of the stocks that may grab investor focus today are:
<ul>
<li>
		Wall Street expects Carnival Corp (NYSE: <a class="ticker" href="/stock/ccl#NYSE">CCL</a>) to report quarterly earnings at $1.88 per share on revenue of $5.06 billion before the opening bell. Carnival shares rose 0.90 percent to close at $47.26 on Friday.</li>
<li>
		Shares of Twitter Inc (NYSE: <a class="ticker" href="/stock/twtr#NYSE">TWTR</a>) surged more than 21 percent Friday following a report from CNBC&#39;s David Faber, that the social media company is preparing to sell itself and has hired Goldman Sachs to handle potential offers. Alphabet Inc (NASDAQ: <a class="ticker" href="/stock/googl#NASDAQ">GOOGL</a>) and salesforce.com, inc. (NYSE: <a class="ticker" href="/stock/crm#NYSE">CRM</a>) are among the potential buyers, according to Faber. The Wall Street Journal reported Sunday that Salesforce CEO Marc Benioff is considering a bid for Twitter and talks between the companies are at an early stage. Verizon Communications Inc. (NYSE: <a class="ticker" href="/stock/vz#NYSE">VZ</a>) is also seen as a potential buyer for Twitter, according to various media reports. Twitter shares surged 21.42 percent to close at $22.62 on Friday.</li>
<li>
		Analysts expect Cal-Maine Foods Inc (NASDAQ: <a class="ticker" href="/stock/calm#NASDAQ">CALM</a>) to report a quarterly loss at $0.22 per share on revenue of $298.36 million before the opening bell. Cal-Maine shares declined 0.09 percent to close at $42.17 on Friday.</li>
</ul>

	Find out what&#39;s going on in today&#39;s market and bring any questions you have to <a href="http://premarket.benzinga.com/pre-market-show/">Benzinga&#39;s PreMarket Prep</a>.
<ul>
<li>
		Before the markets open, Vail Resorts, Inc. (NYSE: <a class="ticker" href="/stock/mtn#NYSE">MTN</a>) is projected to report a quarterly loss at $1.67 per share on revenue of $171.36 million. Vail Resorts shares declined 0.86 percent to close at $160.56 on Friday.</li>
<li>
		LANXESS AG NPV (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) announced Sunday, it has signed a contract to acquire specialty chemicals company Chemtura Corp (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>) for $33.50 per share in cash or $2.5 billion. Chemtura shares gained 2.29 percent to close at $28.18 on Friday.</li>
<li>
		Analysts are expecting Thor Industries, Inc. (NYSE: <a class="ticker" href="/stock/tho#NYSE">THO</a>) to have earned $1.34 per share on revenue of $1.25 billion in the latest quarter. Thor will release earnings after the closing bell. Thor Industries shares slipped 0.45 percent to close at $81.67 on Friday.</li>
<li>
		Apptio Inc (NASDAQ: <a class="ticker" href="/stock/apti#NASDAQ">APTI</a>) shares jumped over 44 percent on its first day of trading. Apptio officially launched its IPO Friday. Initially priced at $16, Apptio went as high as $24.60 on the day. Apptio shares surged 40.94 percent to close at $22.55 on Friday.</li>
</ul>

Earnings

Trading Ideas

APTI

GOOGL

TWTR

Must Watch Stocks for September 26, 2016

Chemtura Trading at $32.94 in Premarket +16.9%; Being Acquired by Lanxess for $33.50/Share

The following are the M&amp;A deals, rumors and chatter circulating on Wall Street for Friday September 23 thru Sunday September 25, 2016:
Twitter Said to be Exploring Sale
The Rumor: Twitter (NYSE: <a class="ticker" href="/stock/twtr#NYSE">TWTR</a>) shares soared Friday following a report from CNBC's David Faber, that the social media company is preparing to sell itself and has hired Goldman Sachs to handle potential offers. Alphabet Inc (NASDAQ: <a class="ticker" href="/stock/googl#NASDAQ">GOOGL</a>) and salesforce.com, inc. (NYSE: <a class="ticker" href="/stock/crm#NYSE">CRM</a>) are among the potential buyers, according to Faber.
The Wall Street Journal reported Sunday that Salesforce CEO Marc Benioff is considering a bid for Twitter and talks between the companies are at an early stage. Verizon (NYSE: <a class="ticker" href="/stock/vz#NYSE">VZ</a>) is also seen as a potential buyer for Twitter, according to various media reports.
Twitter declined comment on the rumor. 
Twitter closed at $22.62 on Friday, up 21.42%.
LANXESS to Acquire Chemtura for $33.50/Share in Cash
The Deal: LANXESS (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) announced Sunday, it has signed a contract to acquire specialty chemicals company Chemtura orporation (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>) for $33.50 per share in cash or $2.5 billion. The transaction is expected to close in mid-2017, subject to approval by Chemtura shareholders.
Chemtura closed at $28.18 on Friday, up 2.29%.
Office Depot to Sell European Operations Aurelius Rho
The Deal: Office Depot, Inc. (NASDAQ: <a class="ticker" href="/stock/odp#NASDAQ">ODP</a>) announced Friday, that it intends to sell its European business to The AURELIUS Group. The transaction is expected to close by the end of 2016.
Office Depot closed at $3.712 on Friday, up $0.08.

Rumors

Benzinga's Weekend M&A Chatter

Chemtura Corporation (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>) today announced that it has entered into a definitive agreement, pursuant to which LANXESS AG (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) will acquire Chemtura in a transaction valued at approximately $2.5 billion. Under the terms of the agreement, Chemtura shareholders will receive $33.50 per share in cash for each outstanding share of common stock held, which represents an 18.9% premium to the stock&#39;s closing share price of $28.18 on September 23, 2016. The respective boards of both companies have unanimously approved the transaction.

	&nbsp;

	&quot;For the past year, our management team and Board of Directors have been actively working to identify a transformative opportunity to create value for our shareholders and to enhance the scale, strength and diversity of our business, both vertically and geographically, for the benefit of our customers and employees. The transaction we are announcing today delivers on that promise,&quot; said Craig A. Rogerson, President, Chief Executive Officer and Chairman of the Board of Chemtura. &quot;It provides premium value to our shareholders and benefits our customers and employees by making Chemtura part of a larger, stronger global enterprise with the resources to fully support a more diverse suite of specialty chemicals products and services.&quot;

	&nbsp;

	Matthias Zachert, Chief Executive Officer and Chairman of the Board of Management of LANXESS, said: &quot;With this acquisition, we are forming a major global player in the field of additives and are significantly strengthening our already profitable portfolio. We are confident that this transaction will create new and exciting opportunities for the customers and employees of both companies. The Chemtura team has built four industrial businesses into a highly attractive group of assets. In addition to the additives segment, Chemtura&#39;s urethane and organometallics businesses will further diversify our company&#39;s product offering.&quot;

	&nbsp;

	Mr. Rogerson concluded: &quot;We believe LANXESS&#39;s offer is recognition of the strength of our business, product portfolio and exceptional global team. I am confident that LANXESS shares Chemtura&#39;s commitment to quality, safety and service and is the right home to ensure a bright future ahead.&quot;

	&nbsp;

	LANXESS will fund the transaction through existing liquidity and the issuance of new debt. The transaction is expected to close around mid-2017, subject to approval by the holders of Chemtura&#39;s common stock, customary closing conditions and regulatory approvals.

	&nbsp;

	Morgan Stanley &amp; Co. LLC acted as financial advisor and Davis Polk &amp; Wardwell LLP acted as legal advisor to Chemtura.

UPDATE: Chemtura to Be Acquired by LANXESS for ~$2.5B in All-Cash Transaction; $33.50/Share

Specialty chemicals company LANXESS (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) has signed a contract to take over the US-based specialty chemicals company Chemtura Corporation (NYSE: <a class="ticker" href="/stock/chmt#NYSE">CHMT</a>). Chemtura is one of the major global providers of high-quality flame retardant- and lubricant additives. LANXESS is offering all cash consideration of USD 33.50 per share.
For the transaction with an enterprise value of around EUR 2.4 billion LANXESS has secured bridge financing. The bridge financing will quickly be refinanced via senior bonds and a hybrid bond. Furthermore, LANXESS will use existing liquidity for financing.
Closing is subject to approval by Chemtura shareholders, any required regulatory approvals and certain other customary closing conditions. Closing of the transaction is anticipated mid-2017.

UPDATE: LANXESS Signs Contract to Acquire Chemtura for $33.50/Share in Cash; Enterprise Value of ~€2.4B

LANXESS to Acquire Chemtura for $33.50/Share in Cash

Lanxess AG (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) reported a 39%% drop in its third quarter net profit. 

Lanxess' quarterly net profit fell to 94 million euro ($120.1 million), while sales dropped 8% to EUR2.2 billion. 

Its adjusted earnings before interest, tax, depreciation and amortization fell 18% to EUR255 million.

Lanxess Q3 Net Profit Down 39% 

Germany's Lanxess AG (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) reported a drop in its second quarter profit.

Its quarterly after-tax profit declined 2.8% y/y to 176 million euros ($216 million). Its sales climbed 8.1% y/y to EUR2.42 billion.

The company's adjusted earnings before interest, tax, depreciation and amortization surged 6.8% to EUR362 million, while earnings per share fell 2.8% to EUR2.11 per share.

Lanxess Posts Decline In Q2 Profit

Lanxess AG (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) reported a rise in profit and sales in the first quarter.

Lanxess' quarterly after-tax profit climbed 16% y/y to EUR193 million. Its sales gained 15% to EUR2.39 billion.

Earnings before interest, taxes, depreciation and amortization surged 15% to EUR369 million. Its earnings per share rose to EUR2.32, from EUR2.

Lanxess Posts Rise In Q1 Profit, Sales

Elizabeth Arden Inc (NASDAQ: <a class="ticker" href="/stock/rden#NASDAQ">RDEN</a>) reported a strong rise in its fiscal fourth-quarter earnings. Elizabeth Arden reported its quarterly profit at $5.4 million, or $0.18 per share, up from $2.3 million, or $0.08 per share, in the year-ago period. Its sales surged 11% to $253.8 million. However, analysts were expecting earnings of $0.10 per share on sales of $243 million. Elizabeth Arden projects current-quarter earnings of $0.25 to $0.30 per share on sales of $295 million to $305 million. Analysts were expecting earnings of $0.26 per share on sales of $296 million.

Wendy's Company (The) (NYSE: <a class="ticker" href="/stock/wen#NYSE">WEN</a>) reported a rise in its second-quarter profit on Thursday. Wendy's quarterly profit surged to $11.3 million from $10.7 million. Its earnings per share came in at $0.03 per share. Its revenue climbed to $622.5 million from $607.4 million. However, analysts were expecting earnings of $0.05 per share on revenue of $758.24 million. Wendy's quarterly same-store sales climbed 2.3%.

Sara Lee Corp (NYSE: <a class="ticker" href="/stock/sle#NYSE">SLE</a>) released its results for the fourth quarter on Thursday. Sara Lee's quarterly earnings dropped to $111 million, or $0.19 per share, from $187 million, or $0.28 per share, in the year-earlier period. Its revenue climbed 9% y/y to $2.30 billion. Its adjusted earnings came in at $0.20 per share. However, analysts were expecting earnings of $0.20 per share on revenue of $2.28 billion. Sara Lee projects net sales for fiscal 2012 of $8.5 billion to $8.75 billion and earnings per share of $0.89 to $0.95 per share.

Anheuser-Busch InBev NV (NYSE: <a class="ticker" href="/stock/bud#NYSE">BUD</a>) reported a 26% rise in its second-quarter net profit. Anheuser-Busch InBev reported its quarterly net profit at $1.45 billion, up from $1.15 billion, in the year-earlier period. Its sales climbed 8.5% to $9.95 billion. Beer volumes in China surged 12% y/y in the second quarter.

Pan American Silver Corp (NASDAQ: <a class="ticker" href="/stock/paas#NASDAQ">PAAS</a>) swung to a second-quarter profit on Thursday. Pan American Silver reported its quarterly profit at $113.5 million, or $1.04 per share, versus a year-ago loss of $5.6 million, or $0.06 per share. Excluding a gain on derivatives and other impacts, Pan American Silver' adjusted earnings came in at $0.71 per share. Its revenue surged 54% to $231.9 million. However, analysts were expecting earnings of $0.75 per share on revenue of $261 million. 

Kohl's Corp (NYSE: <a class="ticker" href="/stock/kss#NYSE">KSS</a>) reported a 16.5% rise in its second-quarter earnings. Kohl's quarterly earnings surged to $303 million, or $1.09 per share, from $260 million, or $0.84 per share, in the year-earlier period. Its revenue rose to $4.25 billion from $4.1 billion. However, analysts were expecting earnings of $1.05 per share on revenue of $4.25 billion. Kohl's raised its 2011 earnings forecast to $4.45 to $4.60 per share, from its prior outlook of $4.25 to $4.40 per share.

Huntington Ingalls Industries Inc (NYSE: <a class="ticker" href="/stock/hii#NYSE">HII</a>) swung to a second-quarter profit on Thursday. Huntington Ingalls reported its quarterly profit at $40 million, or $0.80 per share, versus a loss of $11 million, or $0.23 per share, in the year-ago period. Its sales fell 2.9% to $1.56 billion. However, analysts were expecting earnings of $0.82 per share on sales of $1.65 billion. 

Brinker International Inc (NYSE: <a class="ticker" href="/stock/eat#NYSE">EAT</a>) reported upbeat quarterly profit on Thursday. Brinker's fiscal fourth-quarter net income declined to $41.9 million, or $0.50 per share, from $63.6 million, or $0.62 per share, in the year-ago period. Excluding one-time items, Brinker's earnings came in at $0.48 per share. Its revenue dropped 3.4% to $717.5 million. However, analysts were expecting earnings of $0.47 per share on revenue of $710.57 million.

Tim Hortons Inc (NYSE: <a class="ticker" href="/stock/thi#NYSE">THI</a>) reported a 1.5% increase in its quarterly profit. Tim Hortons' second-quarter earnings surged to C$95.5 million ($95.5 million), or 58 Canadian cents per share, from C$94.1 million, or 54 Canadian cents per share, in the year-earlier period. Its revenue climbed 10% to C$702.8 million.

O'Charley's Inc (NASDAQ: <a class="ticker" href="/stock/chux#NASDAQ">CHUX</a>) reported wider-than-expected second-quarter loss on Thursday. O'Charley's reported a quarterly loss of $1.8 million, or $0.09 per share, versus a loss of $2.5 million, or $0.12 per share, in the year-ago period. Its loss from continuing operations came in at $0.08 per share. Its revenue rose 1% y/y to $193.3 million from $190.9 million. However, analysts were expecting a loss of $0.05 per share on revenue of $189.6 million. O'Charley's projects third-quarter revenue of $185 million to $190 million, versus analysts' estimates of $186.5 million.

Swire Pacific Ltd (OTC: <a class="ticker" href="/stock/swrby#OTC">SWRBY</a>) reported a 64% surge in its first-half net profit. Swire Pacific reported its net profit at HK$23.95 billion, up from HK$14.63 billion, in the year-ago period. Excluding property revaluation gains, Swire Pacific's underlying profit dropped 48% to HK$4.60 billion from HK$8.91 billion. Its revenue climbed 33% to HK$17.08 billion from HK$12.84 billion.

Tata Motors (NYSE: <a class="ticker" href="/stock/ttm#NYSE">TTM</a>) reported a marginal rise its fiscal first quarter profit. Tata reported its quarterly net profit at 19.99 billion rupees, up from 19.89 billion, in the year-ago period. Its consolidated revenue surged 24% y/y to 335.72 billion rupees. However, analysts were expecting a net profit of 21.6 billion rupees on net sales of 329.1 billion.

Zurich Financial Services AG (OTC: <a class="ticker" href="/stock/zfsvy#OTC">ZFSVY</a>) reported an 88% surge in its Q2 net profit. Zurich Financial's quarterly net profit surged to $1.33 billion, from $707 million, in the year-ago period. However, analysts were expecting a net profit of $1.09 billion. Its business volume rose 7% to $17.13 billion. Zurich Financial's income from investments surged to $2.52 billion from $2.01 billion.

Singapore Telecommunications Ltd (OTC: <a class="ticker" href="/stock/sgapy#OTC">SGAPY</a>) reported a 2.9% drop in its fiscal first-quarter net profit. Singtel's quarterly net profit declined to S$916.2 million, from S$943.2 million, in the year-ago period. Analysts were expecting a net profit of S$943.8 million. Pretax profit from SingTel's foreign associates dropped 10% to S$472 million. SingTel's quarterly operating revenue climbed 7.4% to S$4.61 billion from S$4.29 billion.

Lanxess AG (OTC: <a class="ticker" href="/stock/lnxsf#OTC">LNXSF</a>) lifted its projections for the full year on Thursday. Lanxess reported its Q2 net profit at EUR181 million, up from analysts' estimates of EUR160 million. Its sales climbed 23% to EUR2.2 billion. Lanxess' EBITDA before special items gained 26% to EUR339 million, versus analysts' expectations of EUR318 million.

Aegon NV (NYSE: <a class="ticker" href="/stock/aeg#NYSE">AEG</a>) reported a 2.1% drop in its second-quarter net profit. Aegon's quarterly net profit declined to 403 million euros ($575 million), from euro413 million, in the year-ago period. Its revenue dropped 12% to 7.03 billion euros. The group's underlying pretax earnings fell 17% to 401 million euros.

Swisscom AG (OTC: <a class="ticker" href="/stock/scmwy#OTC">SCMWY</a>) lowered its full year sales forecast by CHF300 million. Swisscom's total revenue in the second quarter dropped to CHF2.86 billion from CHF2.99 billion, versus analysts' estimates of CHF2.91 billion. Swisscom's quarterly net profit for shareholders declined to CHF485 million, from CHF494 million, versus estimates of CHF516 million.

CHUX

PAAS

RDEN

SCMWY

SGAPY

SWRBY

ZFSVY

Earnings Roundup

Lanxess AG (OTC: LNXSF) lifted its projections for the full year on Thursday.

Lanxess reported its Q2 net profit at EUR181 million, up from analysts' estimates of EUR160 million. Its sales climbed 23% to EUR2.2 billion. Lanxess' EBITDA before special items gained 26% to EUR339 million, versus analysts' expectations of EUR318 million.

Lanxess shares fell 3.64% to close at $58.30 yesterday.

Guidance

Lanxess Lifts Full-Year Forecast

Lanxess

Comments

Lanxess

Lanxess (LNXSF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga